Home/About/Expertise/Leadership

Have Questions?

Global Headquarters

Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157

North America

Tel: 1-617-573-9450
Fax: 1-617-573-9542

Japan

Tel: +81 (0)80-1164-4754

Request a Demo

What our customers are saying

When I think of the future, I think of EvaluatePharma

Senior Director,
Global pharmaceutical company

Leadership Team

Jonathan de Pass, Founder and Chairman

Dr de Pass, a world-recognized leader in market intelligence and analysis for the life science sector, has led the way in creating new industry standards for forecasting global drug sales and other performance metrics. Prior to founding EvaluatePharma in 1996, Dr. de Pass was a top-ranked pharmaceutical analyst in the London investment-banking arena, where his insights guided venture capital and securities investments. He earned a Masters in Management from the London Business School, and Bachelor of Medicine and Bachelor of Surgery degrees from the University of Bristol in the U.K.

Alex Karle, CEO

Mr Karle joined Evaluate in 2012 as Chief Operating Officer and took on the role of Chief Executive Officer in 2014. Prior to Evaluate, Mr. Karle spent 10 years at Thomson Reuters in various executive roles including Vice President, Business Development & Strategy - IP & Science and General Manager of CMR, a Thomson Reuters business. Mr. Karle began his career as a Senior Associate with Booz Allen & Hamilton’s Media and Communications practice in New York. He holds an MBA from Yale University and a BA (Hons) in Business, Economics and Law from the European Business Programme, Münster, Germany and Hull, United Kingdom.

Jemma Hodson, Chief Commercial Officer

Ms Hodson joined Evaluate in 2014 as Chief Commercial Officer and led creation of Evaluate’s Custom Services business. Ms Hodson also oversees product development and marketing functions. Prior to Evaluate, Ms Hodson was a Principal at Bain & Company, London with over 12 years of consulting experience. Ms Hodson holds an MBA (INSEAD) and BA Modern Languages (Oxford University).

Frank Brilliant, Chief Revenue Officer

Mr Brilliant joined Evaluate in 2017 as Chief Revenue officer bringing over 20 years of executive and Board level experience building, leading global sales, marketing, and product development organizations to achieve significant revenue and EBITA growth. He has broad and diversified success with “high-ticket” enterprise solutions in both Saas and software and service business models. Prior to Evaluate Mr Brilliant held executive management roles at companies including UpToDate, Arch Wireless and Forrester Research.  Mr Brilliant’s business education background includes studies at Boston University, Babson College and Harvard University Executive Management programs.

Nick Southwell, Chief Financial Officer

Mr Southwell joined Evaluate in October 2017 as Chief Financial Officer. He brings over 25 years of executive level finance, change management and business process improvement expertise. Mr Southwell served as interim CFO to various investor fuelled growth companies while a consultant for Maxxim Consulting and Avisen PLC in London. Prior to that, Mr Southwell held positions as Finance Director at Hilding Anders UK PLC and as Controller at EMEA – FD Agri Products Limited. Earlier work included financial management positions at European FC Union and in Du Pont Chemical businesses. 

Dee Periyannen, Chief Technology Officer

Mr Periyannen joined Evaluate in 2010 as Head of Project Portfolio Management and is now Chief Technology Officer.  Mr Periyannen is responsible for the Software Development, IT and Project Management and defines scalable, agile development processes, ensuring platform stability and professional project delivery practices. Previously, Mr Periyannen served as a senior-level Project Manager delivering commercial IT/bus. change projects at Siemens. He holds an BSc Medical Biochemistry (University of Leeds).

Anthony Raeside, Head of Research

Mr Raeside leads Evaluate's analyst teams, currently numbering over 95 staff globally, providing life science sector analysis and commercial insight into the biotechnology, pharmaceutical and medical device industries. He joined EvaluatePharma in 1997 and has been responsible for content development and strategy, to continually enhance the value of Evaluate services to its client base. He is an economics graduate of the London School of Economics and Political Science.